Sign in

    Jon Young

    Director and Equity Research Analyst at Canaccord Genuity Group Inc.

    Jon Young is a Director and Equity Research Analyst at Canaccord Genuity Group, specializing in the healthcare sector with a focus on medical devices and supplies. He covers companies such as Merit Medical Systems, STAAR Surgical, and Pulmonx, with a recent track record that includes a 33% success rate and an average return of -15.29% based on 15 ratings. Young has over 30 years of experience in the finance industry, with his current tenure at Canaccord Genuity following a broad background in corporate and general business experience in portfolio management. He holds FINRA-equivalent credentials, is authorized to provide securities advice, and is accredited as a Certified Financial Planner (CFP).

    Jon Young's questions to ANGIODYNAMICS (ANGO) leadership

    Jon Young's questions to ANGIODYNAMICS (ANGO) leadership • Q4 2025

    Question

    Jon Young of Canaccord Genuity Group Inc. inquired about the regulatory pathway for the AlphaVac blood return product, whether the current product is facing a revenue ceiling, and if the MedTech guidance anticipates a significant inflection for NanoKnife after its new reimbursement code becomes effective in January 2026.

    Answer

    President and CEO Jim Clemmer explained that the AlphaVac blood return feature is an ancillary add-on requiring a 510(k) process, with discussions ongoing with the FDA. He asserted that AlphaVac is not hitting a revenue ceiling, citing growing hospital approvals and synergistic selling with AngioVac, and expects continued sequential growth. EVP and CFO Steve Trowbridge added that while NanoKnife growth will accelerate with reimbursement, it will not be an immediate "light switch" but a more gradual ramp in the second half of the fiscal year.

    Ask Fintool Equity Research AI

    Jon Young's questions to Ceribell (CBLL) leadership

    Jon Young's questions to Ceribell (CBLL) leadership • Q1 2025

    Question

    Jon Young inquired about the pricing assumptions factored into the gross margin guidance and the company's ability to raise prices. He followed up by asking how quickly tariff-related price increases could be implemented given customer contract structures.

    Answer

    CFO Scott Blumberg stated the current margin guidance does not assume any new price increases, though he noted customers have been receptive to past increases due to the value delivered. He explained that since contracts are typically annual and expire on a rolling basis, any price changes would be implemented gradually as individual contracts come up for renewal.

    Ask Fintool Equity Research AI

    Jon Young's questions to Ceribell (CBLL) leadership • Q1 2025

    Question

    Jon Young inquired about the pricing assumptions factored into the gross margin commentary and asked about Ceribell's ability to raise prices in the current macroeconomic environment, including how receptive hospitals have been.

    Answer

    CFO Scott Blumberg clarified that the current gross margin guidance does not assume any changes in pricing policy or any new tariff-related price increases. He noted that customers have been receptive to appropriate price increases in the past due to the value Ceribell delivers. He also mentioned that contracts are typically for one to two years and expire on a rolling basis, governing the timing of any price adjustments.

    Ask Fintool Equity Research AI